Nevakar, LLC   Report issue

For profit Phase 2 Phase 3
Founded: Bridgewater NJ United States (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2017
NCT03350620
First Marketed Drug
2020
ephedrine
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

NEVAKAR | Nevakar, Inc | Nevakar, Inc. | NEVAKAR INJECTABLES | Nevakar Injectables, Inc. | Nevakar, LLC

Active Ingredients

Marketed Drugs (2)

cyclophosphamide (cytoxan) (2023)

ephedrine (2020)

Drugs in Phase 3 Trials (1)

atropine (1 trial)

Drugs in Phase 2 Trials (3)

acetaminophen (tylenol) (4 trials)

exp039 (1 trial)

pregabalin (lyrica) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myopia (Phase 3)

Pain, Postoperative (Phase 2)

Toothache (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 4